Healthcare Industry News: sanofi-aventis
News Release - April 4, 2011
Shionogi Announces New US LeadershipFLORHAM PARK, N.J.--(Healthcare Sales & Marketing Network)-- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has named Dr. John Keller as President and Chief Executive Officer. Dr. Keller has served as Executive Vice President of Corporate Development and Strategy at the Company since July 2010. Dr. Keller succeeds Dr. Sapan Shah, who has made a decision to leave the Company.
Since July 2010, Shionogi Inc. has been the consolidated US corporate headquarters of Shionogi & Co., Ltd., based in New Jersey, overseeing all US operations for Shionogi group, including the sales, marketing, and distribution subsidiary, Shionogi Pharma, Inc., based in Atlanta, Georgia, and the clinical development and regulatory operations, Shionogi USA, Inc., based in New Jersey. As of April 1st, the integration and consolidation of all of Shionogi’s US subsidiaries and operations into Shionogi Inc., has been completed and will now move forward under the leadership of Dr. Keller.
Dr. Keller said, “First of all, I greatly appreciate Dr. Shah’s enormous contributions to Shionogi over more than nine years with the group, first, as CEO of Shionogi USA, Inc., and then, beginning in 2010, as CEO of Shionogi Inc. In that latter role, he undertook the reorganization of our US business in the face of numerous challenges and has laid the groundwork for the future of Shionogi’s US business, including recruiting a new US leadership team, increasing the reliability of our supply chain network, and integrating and improving the efficiency of many aspects of our business. He also played a key role in the management of our joint venture with ViiV Healthcare for the pursuit of novel HIV therapies. Due to the efforts of Dr. Shah and the new executive leadership team, and most of all, the dedication of our US employees, the Company is now in a much stronger position.
I look forward to leading our US business into its next phase, in which we will strengthen our product portfolio and revitalize our commercial organization under the leadership of Deanne Melloy, who has been promoted to Chief Operating Officer. We expect these actions will establish not only financial stability but also growth, and we look forward to updating you on our progress. We will also deepen our integration with our parent company to assure that Shionogi Inc. is optimally positioned to support the development and commercialization of Shionogi’s pipeline products in the US.”
Dr. Keller joined Shionogi Inc. in July 2010, and has been responsible for corporate and business development, alliance management, and strategic planning. Prior to joining Shionogi, Dr. Keller served as a Partner of SR One, the venture capital arm of GlaxoSmithKline and, before that, as Executive Vice President and Chief Business Officer of Incyte Corporation. He began his career at SmithKline Beecham, progressing through a series of scientific and business roles over a 16 year tenure, culminating in the position of Vice President, Worldwide Business Development, GlaxoSmithKline.
Deanne Melloy joined Shionogi Inc. in January 2011, and has been leading Shionogi’s commercial activities in the US as Executive Vice President and Chief Commercial Officer of the Company. Prior to joining Shionogi, Ms. Melloy was Vice President of the General Therapeutics and Lifecycle Management business unit at sanofi-aventis, where she was responsible for the product contribution of multiple brands, new product launches as well as overseeing the lifecycle management for all US products. Prior to sanofi-aventis, Ms. Melloy was with Endo Pharmaceuticals, most recently as Vice President, Marketing, where she had commercial responsibility for a $1.3B product portfolio, including leading, managing and launching new products. Ms. Melloy’s career also includes seven years with Ortho Biotech, a Johnson and Johnson company, where she held roles of increasing responsibility in the areas of sales and marketing. Earlier in her career, she held sales positions with EMPI Inc., and Medtronic.
About Shionogi & Co., Ltd.
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Inc., headquartered in Florham Park, NJ, please visit www.shionogi-inc.com.
Forward Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.